All research products on this site, including all peptides, are sold strictly for laboratory and research use only, not for human or animal consumption, diagnostic, or therapeutic use. Our tallow skincare products are topical cosmetics. You must be 21 or older to enter.
By entering you confirm you are 21+ and accept these products are for research use only. See our Terms and Disclaimer.
For laboratory research. Sold in 30mg and 300mg kit sizes.
Complete the order
Supplies and compounds researchers add to this order
Identity, purity and handling data for this compound, in one place. Tap an identifier to copy it.
A third-party certificate for Sema is not published here yet. If your work needs one, ask us before ordering and we will tell you what testing is available for the current lot.
Ask about a certificateFor research use only. Not for human consumption.
Semaglutide is a 31-amino acid GLP-1 receptor agonist peptide engineered from the native human glucagon-like peptide-1 (7-36) sequence. Two structural changes distinguish it from endogenous GLP-1: an alanine-to-2-aminoisobutyric acid (Aib) substitution at position 8 that blocks DPP-4 enzymatic cleavage, and a C18 fatty diacid side chain conjugated at lysine-26 through a gamma-glutamate and two-unit polyethylene glycol spacer. In research contexts this combination is what separates sema from earlier-generation GLP-1 analogues such as liraglutide, which carries a shorter C16 palmitic acid chain and a markedly shorter plasma half-life profile in comparative pharmacokinetic study designs. ORP supplies the compound as a lyophilized powder for laboratory characterization work only.
As a GLP-1 research peptide, sema's pharmacology centers on activation of the class B G-protein-coupled GLP-1 receptor, which couples primarily to Gs and drives adenylate cyclase-mediated cAMP accumulation and downstream PKA and Epac2 signaling. In pancreatic beta-cell research models this cascade has been linked to glucose-dependent insulinotropic signaling, while in alpha-cell systems the same receptor pathway is associated with suppressed glucagon output. GLP-1 receptor expression extends past the endocrine pancreas into hypothalamic and brainstem nuclei, cardiac myocytes, renal tubular cells, and hepatocytes, which is why sema appears across a wide span of receptor-distribution and signal-transduction literature rather than a single organ system.
Sema peptide research spans in vitro and in vivo experimental systems. Common in vitro platforms include GLP-1R-transfected HEK293 cell lines and INS-1 or MIN6 beta-cell lines used for cAMP accumulation assays, receptor binding and internalization studies, and glucose-stimulated insulin secretion protocols. In vivo, diet-induced obese mice and Zucker diabetic fatty rats are frequently referenced rodent models for examining gastric emptying kinetics, hypothalamic feeding-circuit activity, and beta-cell mass endpoints under controlled laboratory conditions.
Review the product specifications and available batch-specific reports for semaglutide before ordering. Check which identity and purity tests the report records, and whether it applies to the product and lot you are considering. These research materials are not intended for human or animal use.
Semaglutide reconstitution in the laboratory follows standard lyophilized-peptide handling practice: the sealed vial is brought to room temperature, a calculated volume of bacteriostatic water or another appropriate diluent is added slowly down the interior wall of the vial, and the contents are swirled gently rather than shaken to avoid mechanical denaturation and foaming of the peptide. Once reconstituted, the solution should be inspected for clarity, protected from light, and stored refrigerated at 2-8C for short-term bench use, since repeated freeze-thaw cycles and room-temperature storage degrade peptide integrity over time. Unreconstituted lyophilized powder is more stable and is typically kept frozen at -20C until the point of use in a research protocol. These handling notes describe laboratory solution preparation only and are not administration or dosing instructions for humans or animals.
Contact us for handling and batch documentation for semaglutide research materials. A laboratory should assess the documentation for the particular material and lot before beginning research.
All sema peptide products distributed by Optimum ReGen Peptides are intended strictly for in vitro and preclinical laboratory research by qualified personnel. Nothing in this description constitutes medical advice or a claim of human benefit, and the product has not been evaluated for diagnosing, treating, curing, or preventing any disease. This peptide is not for human consumption and should be handled with standard laboratory personal protective equipment under an institution's chemical hygiene plan.
The areas where this compound appears in the published research literature.
Pharmacological characterization of sema at the GLP-1 receptor uses cAMP accumulation assays in GLP-1R-expressing HEK293 cells, radioligand competition binding with [125I]-GLP-1 or [3H]-exendin-4, and beta-arrestin recruitment BRET assays to determine binding affinity, efficacy, and biased agonism profiles. These in vitro studies establish the compound's receptor pharmacology independent of pharmacokinetic variables.
Beta-cell secretion studies use isolated pancreatic islets from rodent or human donors, exposing them to sema at defined concentrations during glucose-stimulated insulin secretion (GSIS) assays. Researchers measure insulin, C-peptide, and glucagon release by ELISA, and assess islet gene expression using RNA sequencing or targeted qPCR panels to characterize transcriptional responses to prolonged GLP-1R activation.
In vivo metabolic research employs diet-induced obesity mouse models (DIO C57BL/6) or genetic diabetic models (db/db, ob/ob) under controlled conditions and comprehensive metabolic phenotyping including indirect calorimetry, glucose and insulin tolerance tests, body composition by NMR or DXA, and tissue-level molecular profiling of liver, fat, and muscle samples.
Lyophilized sema research material should be stored at -20°C, protected from light and humidity. The fatty acid modification that enables albumin binding is stable under these conditions. Vials should be sealed with Parafilm or similar barrier material and equilibrated to room temperature under desiccant before opening.
Reconstituted sema solutions for in vitro use should be prepared in phosphate-buffered saline (pH 7.4) or similar physiological buffers and held at 4°C for up to one week given the compound's inherent stability. For in vivo studies, researchers prepare solutions fresh and keep them cold. Glass vials are preferred over polypropylene to minimize peptide adsorption.
Sema (Semaglutide) for sale from Optimum ReGen Peptides, a US research-peptide company with a storefront in Medford, Oregon. It is in stock, priced from $125. Every order ships 2-Day Priority Air, a $13 flat rate anywhere in the US, with tracking, or can be picked up at the store.
Sema is supplied as lyophilized powder, for laboratory and research use only, not for human consumption.
